Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo- and Active-controlled, Randomised, Double-blind, Dose-escalation Phase I Study of IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics With the Exploration on Its Pharmacodynamics and Efficacy

Next Previous
X
Search
Trial Profile

A Placebo- and Active-controlled, Randomised, Double-blind, Dose-escalation Phase I Study of IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics With the Exploration on Its Pharmacodynamics and Efficacy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IDG 16177 (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Ildong Pharmaceutical

    • Most Recent Events

    • 09 Jul 2021 New trial record
    • 01 Jul 2021 According to an Ildong Pharmaceutical media release, the company has initiated this study and aims to complete this study by 2022.
    • 01 Jul 2021 According to an Ildong Pharmaceutical media release, on 28 June 2021, the company has received approval from the Federal Institute for Drugs and Medical Devices (BfArM) of German regulatory authority for this study. Based on this approval, the company will immediately commence Phase 1 study in Berlin, Germany.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top